Article

Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study

Department of Orthopedics, Assaf Harofeh Medical Center, Zerifin, Israel.
BMC Complementary and Alternative Medicine (Impact Factor: 1.88). 06/2011; 11(1):50. DOI: 10.1186/1472-6882-11-50
Source: PubMed

ABSTRACT Patients with osteoarthritis (OA) take a variety of health supplements in an attempt to reduce pain and improve function. The aim of this study was to determine the efficacy of methylsulfonylmethane (MSM) in treating patients with knee OA.
This study was a prospective, randomized, double-blind, controlled clinical trial. Forty nine men and women 45-90 (mean 68 ± SD 7.3) years of age with knee OA according to the American College of Rheumatology clinical criteria for OA of the knee and with radiographic confirmed knee OA were enrolled in the study and randomly assigned into 2 groups: One received MSM in doses of 1.125 grams 3 times daily for 12 weeks and the other received a placebo in the same dosing frequency. The primary outcomes were the WOMAC Osteoarthritis Index for pain, stiffness and physical function, the Aggregated Locomotor Function (ALF) test that evaluates each patient's physical function, the SF-36 quality of life health survey and the visual-analogue-scale (VAS) for pain. The secondary outcomes were Knee Society Clinical Rating System for Knee Score (KSKS) and Function Score (KSFS). Patients were assessed at baseline, 6 weeks and 12 weeks. All continuous variables were tested by the Kolmogorov-Smirnov test for Normal distribution. Changes within the groups and differences between the groups were calculated by repeated measures of analysis (ANOVA) with one nested variable.
There were significant differences between treatment groups over time in WOMAC physical function (14.6 mm [CI: 4.3, 25.0]; p = 0.04) and in WOMAC total score (15.0 mm [CI: 5.1, 24.9]; p = 0.03). Treatment groups did not differ significantly in WOMAC pain (12.4 mm [CI: 0.0, 24.8]); p = 0.08) or WOMAC stiffness (27.2 mm [CI: 8.2, 46.2]; p = 0.08). There was a non-significant difference in SF-36 total score between treatment groups (11.6 [CI: 1.0, 22.1]; p = 0.54). A significant difference was found between groups in VAS for pain (0.7 s [CI: -0.9, 2.4]; p = 0.05). Secondary outcomes showed non-significant differences between the two groups.
Patients with OA of the knee taking MSM for 12 weeks showed an improvement in pain and physical function. These improvements, however, are small and it is yet to be determined if they are of clinical significance.
ClinicalTrials.gov: NCT01188213.

Download full-text

Full-text

Available from: Gabriel Agar, Aug 31, 2015
0 Followers
 · 
163 Views
    • "Next, methylsulfonylmethane (MSM), organic sulfur, was shown to be effective in OA model mice,[12] by decreasing the degeneration of the cartilage at the knee's joint surfaces. MSM used in humans, Debbi, et al.,[13] demonstrated a decrease in pain (via the Visual Analog Scale; [VAS]) and an increase in physical function (via the Western Ontario and McMaster University Osteoartirhits Index; [WOMAC]) compared to a placebo. Capsaicin is a neuromodulator and has been recommended as ‘an add-on therapy for patients with persistent local pain and inadequate response or intolerance to other treatments’.[14] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Arthritis affects both the physical and psychological abilities of people in all walks of life. There are currently no recommended effective 'disease-modifying' remedies. Therapists and physicians are therefore exploring possible benefits from non-conventional therapeutic approaches. The purpose is to assess the changes in fitness and psychosocial outcomes of six doctor-referred patients as a result of participating in the I Can Move Again (ICMA) program. Six female participants diagnosed with arthritis were recruited from a local family practitioner. The subjects participated in a series of daily classes for 12 weeks including massage, mindfulness, bounce-back chairs, resistance chairs, aerobic and anaerobic training, rebounders, and whole body vibration platform Tai Chi. Demographic, psychosocial, and physical data were collected at the ICMA and at Y-Be-Fit (Provo, UT). Significant pre to post mean differences were found for sit-ups (F (1,8) =5.42 P =0.048), chair stand (F (1,10) =6.622 P =0.028), arm curl (F (1,10) =14.379 P =0.004), six-minute walk test distance (F (1,9)= 19.188 P=0.002), and speed (F,(1,8) =13.984 P =0.006), and rotation right (F (1,10) =8.921 P =0.014) and left (F (1,10) =11.373 P =0.007), in 27 of the 61-item questionnaire. The preliminary data on the six subjects lacked sufficient statistical power to detect the significant differences that could exist, thus committing a Type II error, but it is important to note an overall, substantial trend in improvement in the patients' physical outcomes and psychosocial perceptions associated with improvements in activities of daily living.
    04/2014; 4(2):99-107. DOI:10.4103/2225-4110.124364
  • Source
    • "OA, which is manifested by joint pain, disability, stiffness, and/or swelling, is a common chronic disease in the elderly worldwide [1] [2] [3]. In Traditional Chinese Medicine (TCM), symptoms of OA are usually known as " Bi-arthralgia " or " flaccidity " [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. The aim of this study is to systematically evaluate the evidence whether traditional Chinese herbal patches (TCHPs) for osteoarthritis (OA) are effective and safe and analyze their medication patterns. Methods. A systematic literature search was performed using all the possible Medical Subject Headings (MeSH) and keywords from January 1979 to July 2013. Both randomized controlled trials (RCTs) and observational studies were included. Estimated effects were analyzed using mean difference (MD) or relative risk (RR) with 95% confidence intervals (CI) and meta-analysis. Results. 86 kinds of TCHPs were identified. RCTs and controlled clinical trials (CCTs) which were mostly of low quality favored TCHPs for local pain and dysfunction relief. TCHPs, compared with diclofenac ointment, had significant effects on global effectiveness rate (RR = 0.50; 95% CI (0.29, 0.87)). Components of formulae were mainly based on the compounds "Xiao Huo Luo Dan" (Minor collateral-freeing pill) and "Du Huo Ji Sheng Tang" (Angelicae Pubescentis and Loranthi decoction). Ten kinds of adverse events (AEs), mainly consisting of itching and/or local skin rashes, were identified after 3-4 weeks of follow-up. Conclusions. TCHPs have certain evidence in improving global effectiveness rate for OA; however, more rigorous studies are warranted to support their use.
    Evidence-based Complementary and Alternative Medicine 01/2014; 2014:343176. DOI:10.1155/2014/343176 · 1.88 Impact Factor
  • Source
    • "The Instaflex™ Joint Support supplement (Instaflex) (Direct Digital, Charlotte, NC) features a cocktail of eight chondroprotective and anti-inflammatory ingredients that may relieve joint pain discomfort and improve function. Ingredients include glucosamine sulfate [12], methylsufonlylmethane [13-15], white willow bark extract [16], ginger root concentrate [17,18], Boswella serrata extract [19,20], turmeric root extract [21], cayenne [22], and hyaluronic acid [23]. Each of these ingredients has been studied separately providing some scientific support for alleviation of joint pain, but the composite product has not yet been tested in humans using a randomized, double-blinded, placebo-controlled research design. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to assess the effect of 8-weeks ingestion of a commercialized joint pain dietary supplement (InstaflexTM Joint Support, Direct Digital, Charlotte, NC) compared to placebo on joint pain, stiffness, and function in adults with self-reported joint pain. InstaflexTM is a joint pain supplement containing glucosamine sulfate, methylsufonlylmethane (MSM), white willow bark extract (15% salicin), ginger root concentrate, boswella serrata extract (65% boswellic acid), turmeric root extract, cayenne, and hyaluronic acid. Subjects included 100 men and women, ages 50-75 years, with a history (>3 months) of joint pain, and were randomized to InstaflexTM or placebo (3 colored gel capsules per day for 8 weeks, double-blind administration). Subjects agreed to avoid the use of non-steroidal anti-inflammatory drugs (NSAID) and all other medications and supplements targeted for joint pain. Primary outcome measures were obtained pre- and post-study and included joint pain severity, stiffness, and function (Western Ontario and McMaster Universities [WOMAC]), and secondary outcome measures included health-related quality of life (Short Form 36 or SF-36), systemic inflammation (serum C-reactive protein and 9 plasma cytokines), and physical function (6-minute walk test). Joint pain symptom severity was assessed bi-weekly using a 12-point Likert visual scale (12-VS). Joint pain severity was significantly reduced in InstaflexTM compared to placebo (8-week WOMAC, [downwards arrow]37% versus [downwards arrow]16%, respectively, interaction effect P = 0.025), with group differences using the 12-VS emerging by week 4 of the study (interaction effect, P = 0.0125). Improvements in ability to perform daily activities and stiffness scores in InstaflexTM compared to placebo were most evident for the 74% of subjects reporting knee pain (8-week WOMAC function score, [downwards arrow]39% versus [downwards arrow]14%, respectively, interaction effect P = 0.027; stiffness score, [downwards arrow]30% versus [downwards arrow]12%, respectively, interaction effect P = 0.081). Patterns of change in SF-36, systemic inflammation biomarkers, and the 6-minute walk test did not differ significantly between groups during the 8-week study CONCLUSIONS: Results from this randomized, double blind, placebo-controlled community trial support the use of the InstaflexTM dietary supplement in alleviating joint pain severity in middle-aged and older adults, with mitigation of difficulty performing daily activities most apparent in subjects with knee pain.Trial registration: ClinicalTrials.gov Identifier: NCT01956500.
    Nutrition Journal 11/2013; 12(1):154. DOI:10.1186/1475-2891-12-154 · 2.64 Impact Factor
Show more